Submit your email to push it up the queue
Medicaroid Corporation, headquartered in Japan, is a pioneering force in the robotics and healthcare industry. Founded in 2015, the company has rapidly established itself as a leader in developing advanced robotic solutions for medical applications, particularly in rehabilitation and assistive technologies. With a focus on enhancing patient care, Medicaroid's core products include innovative robotic systems designed to support physical therapy and improve mobility for individuals with disabilities. Their unique approach combines cutting-edge technology with user-friendly interfaces, setting them apart in a competitive market. Recognised for their commitment to quality and innovation, Medicaroid has achieved significant milestones, including collaborations with leading healthcare institutions. As they continue to expand their operational reach, their dedication to improving healthcare outcomes positions them as a key player in the global medical robotics landscape.
How does Medicaroid Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Computer Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Medicaroid Corporation's score of 64 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Medicaroid Corporation, headquartered in Japan (JP), currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. However, the company is part of a corporate family that includes Sysmex Corporation, from which it inherits climate-related initiatives and targets. Medicaroid's climate commitments are influenced by its relationship with Sysmex Corporation, which has established science-based targets (SBTi) and participates in the Carbon Disclosure Project (CDP). These initiatives aim to enhance transparency and accountability in carbon emissions management. While specific reduction targets for Medicaroid are not detailed, the overarching goals set by Sysmex Corporation guide its climate strategy. As a current subsidiary of Sysmex, Medicaroid aligns its sustainability efforts with the parent company's initiatives, although no specific reduction achievements or targets have been disclosed at this time. The absence of direct emissions data suggests that Medicaroid is in the early stages of formalising its climate commitments, reflecting a broader industry trend towards increased environmental responsibility.
Access structured emissions data, company-specific emission factors, and source documents
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|
Scope 1 | 5,559,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 20,278,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
Scope 3 | - | 00,000,000 | 00,000,000 | 00,000,000 | - | - | - | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Medicaroid Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.